CD274 and glioblastoma: In recurrent GBM cases with higher mutations and where immunotherapy resistance is expected less, we also found PD-L1 expression lower than those which are nonrecurrent (44.5% and 51.0%, respectively), similar to the studies of Berghof, Heynckes, and Ndom [13,14,18].